Gastritis classification: Difference between revisions
No edit summary |
No edit summary |
||
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
The Updated Sydney System establishes the classification and grading of gastritis which underlines the significance of combining topographical, morphological, and etiological information to help arrive at clinical diagnosis. In clinical practice, | The Updated Sydney System establishes the classification and grading of gastritis which underlines the significance of combining topographical, morphological, and etiological information to help arrive at clinical diagnosis. In clinical practice, gastritis staging is done using the OLGA (Operative Link on Gastritis Assessment) staging system for reporting [[gastric]] histology. Gastritis staging combines the [[atrophy]] score which is determined by biopsy and the [[atrophy]] topography which is determined by directed [[biopsy]] mapping. | ||
==Classification== | ==Classification== | ||
*The Updated Sydney System establishes the classification and grading of gastritis which underlines the significance of combining topographical, morphological, and etiological information to help arrive at clinical diagnosis. <ref name="pmid8827022">{{cite journal| author=Dixon MF, Genta RM, Yardley JH, Correa P| title=Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. | journal=Am J Surg Pathol | year= 1996 | volume= 20 | issue= 10 | pages= 1161-81 | pmid=8827022 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8827022 }} </ref> | *The Updated Sydney System establishes the classification and grading of gastritis which underlines the significance of combining topographical, morphological, and etiological information to help arrive at clinical diagnosis. <ref name="pmid8827022">{{cite journal| author=Dixon MF, Genta RM, Yardley JH, Correa P| title=Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. | journal=Am J Surg Pathol | year= 1996 | volume= 20 | issue= 10 | pages= 1161-81 | pmid=8827022 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8827022 }} </ref><br /> | ||
<br /> | |||
{| | {| | ||
! colspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" + |'''Classification and grading of Gastritis: Updated Sydney System''' | ! colspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" + |'''Classification and grading of Gastritis: Updated Sydney System''' | ||
Line 18: | Line 17: | ||
| colspan="2" style="background:#DCDCDC;" align="center" + | Non-atrophic | | colspan="2" style="background:#DCDCDC;" align="center" + | Non-atrophic | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Helicobacter pylori | *''[[Helicobacter pylori]]'' | ||
*Other factors | *Other factors | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
Line 31: | Line 30: | ||
| style="background:#DCDCDC;" align="center" + |Autoimmune | | style="background:#DCDCDC;" align="center" + |Autoimmune | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Autoimmunity | *[[Autoimmunity]] | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Type A* | *Type A* | ||
*Diffuse corporal | *Diffuse corporal | ||
*Pernicious anemia-associated | *[[Pernicious anemia]]-associated | ||
|- | |- | ||
| rowspan="3" style="background:#DCDCDC;" align="center" + |Multifocal atrophic | | rowspan="3" style="background:#DCDCDC;" align="center" + |Multifocal atrophic | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Helicobacter pylori | *''[[Helicobacter pylori]]'' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Type B*, type AB* | *Type B*, type AB* | ||
Line 61: | Line 60: | ||
|- | |- | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Bile | *[[Bile]] | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Reflux | *Reflux | ||
|- | |- | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*NSAIDs | *[[NSAIDs]] | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*NSAID | *[[NSAID]] | ||
|- | |- | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
Line 77: | Line 76: | ||
| style="background:#DCDCDC;" align="center" + |Radiation | | style="background:#DCDCDC;" align="center" + |Radiation | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Radiation injury | *[[Radiation injury]] | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
|- | |- | ||
| rowspan="4" style="background:#DCDCDC;" align="center" + |Lymphocytic | | rowspan="4" style="background:#DCDCDC;" align="center" + |Lymphocytic | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Idiopathic? Immune mechanisms | *Idiopathic? [[Immune]] mechanisms | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Varioliform (endoscopic) | *Varioliform ([[endoscopic]]) | ||
|- | |- | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Gluten | *[[Gluten]] | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Celiac disease-associated | *[[Celiac disease]]-associated | ||
|- | |- | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Drug (ticlopidine) | *Drug ([[ticlopidine]]) | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
|- | |- | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
* | *''[[Helicobacter pylori]]'' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
|- | |- | ||
| rowspan="5" style="background:#DCDCDC;" align="center" + |Noninfectious granulomatous | | rowspan="5" style="background:#DCDCDC;" align="center" + |Noninfectious granulomatous | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Crohn's disease | *[[Crohn's disease]] | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
|- | |- | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Sarcoidosis | *[[Sarcoidosis]] | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
|- | |- | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Granulomatosis with polyangiitis and other vasculitides | *[[Granulomatosis with polyangiitis]] and other [[vasculitides]] | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
|- | |- | ||
Line 119: | Line 118: | ||
*Idiopathic | *Idiopathic | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Isolated granulomatous | *Isolated [[granulomatous]] | ||
|- | |- | ||
| rowspan="2" style="background:#DCDCDC;" align="center" + |Eosinophilic | | rowspan="2" style="background:#DCDCDC;" align="center" + |Eosinophilic | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Food sensitivity | *[[Food allergy|Food sensitivity]] | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Allergic | *[[Allergic]] | ||
|- | |- | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Other allergies | *Other [[allergies]] | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
|- | |- | ||
| rowspan="2" style="background:#DCDCDC;" align="center" + |Other infectious gastritides | | rowspan="2" style="background:#DCDCDC;" align="center" + |Other infectious gastritides | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Bacteria (other than | *[[Bacteria]] (other than ''[[Helicobacter pylori]]'') | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Phlegmonous | *Phlegmonous | ||
|- | |- | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Viruses | *[[Viruses]] | ||
*Fungi | *[[Fungi]] | ||
*Parasites | *[[Parasites]] | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
|} | |} |
Revision as of 15:33, 28 December 2017
Gastritis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Gastritis classification On the Web |
American Roentgen Ray Society Images of Gastritis classification |
Risk calculators and risk factors for Gastritis classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Reddy Kothagadi M.B.B.S[2]}}
Overview
The Updated Sydney System establishes the classification and grading of gastritis which underlines the significance of combining topographical, morphological, and etiological information to help arrive at clinical diagnosis. In clinical practice, gastritis staging is done using the OLGA (Operative Link on Gastritis Assessment) staging system for reporting gastric histology. Gastritis staging combines the atrophy score which is determined by biopsy and the atrophy topography which is determined by directed biopsy mapping.
Classification
- The Updated Sydney System establishes the classification and grading of gastritis which underlines the significance of combining topographical, morphological, and etiological information to help arrive at clinical diagnosis. [1]
Classification and grading of Gastritis: Updated Sydney System | |||
---|---|---|---|
Type of Gastritis | Etiology | Gastritis synonyms | |
Non-atrophic |
|
| |
Atrophic | Autoimmune |
| |
Multifocal atrophic |
| ||
|
| ||
|
| ||
Special forms | Chemical |
|
|
| |||
|
| ||
Radiation | |||
Lymphocytic |
|
| |
| |||
|
|||
Noninfectious granulomatous | |||
|
|||
|
|||
|
| ||
Eosinophilic | |||
|
|||
Other infectious gastritides |
|
| |
- In clinical practice, Gastritis staging is done using the OLGA (Operative Link on Gastritis Assessment) staging system for reporting gastric histology. Gastritis staging combines the atrophy score which is determined by biopsy and the atrophy topography which is determined by directed biopsy mapping. [2] [3]
Gastritis staging in clinical practice: The OLGA staging system | |||||
---|---|---|---|---|---|
Atrophy Score | Corpus | ||||
No Atrophy (Score: 0) | Mild Atrophy (Score: 1) | Moderate Atrophy (Score: 2) | Severe Atrophy (Score: 3) | ||
A N T R U M |
No Atrophy (Score: 0) (including incisura angularis) | STAGE 0 | STAGE I | STAGE II | STAGE II |
Mild Atrophy (Score: 1) (including incisura angularis) | STAGE I | STAGE I | STAGE II | STAGE III | |
Moderate Atrophy (Score: 2) (including incisura angularis) | STAGE II | STAGE II | STAGE III | STAGE IV | |
Severe Atrophy (Score: 3) (including incisura angularis) | STAGE III | STAGE III | STAGE IV | STAGE IV |
Sydney system for grading of chronic gastritis[1]
Sydney system for grading of Chronic Gastritis | ||
---|---|---|
Feature | Definition | Grading guidelines |
Chronic inflammation |
|
|
Activity |
|
|
Atrophy |
|
|
Helicobacter pylori |
|
|
Intestinal Metaplasia |
|
|
References
- ↑ 1.0 1.1 Dixon MF, Genta RM, Yardley JH, Correa P (1996). "Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994". Am J Surg Pathol. 20 (10): 1161–81. PMID 8827022.
- ↑ Rugge M, Meggio A, Pennelli G, Piscioli F, Giacomelli L, De Pretis G; et al. (2007). "Gastritis staging in clinical practice: the OLGA staging system". Gut. 56 (5): 631–6. doi:10.1136/gut.2006.106666. PMC 1942143. PMID 17142647.
- ↑ Rugge M, Correa P, Di Mario F, El-Omar E, Fiocca R, Geboes K; et al. (2008). "OLGA staging for gastritis: a tutorial". Dig Liver Dis. 40 (8): 650–8. doi:10.1016/j.dld.2008.02.030. PMID 18424244.